Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis [Yahoo! Finance]
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis